Variables | Total (%) (n = 1860) | HR (%) (n = 218) | non-HR (%) (n = 1642) | χ2/Z | P |
---|---|---|---|---|---|
Transmission route | Â | Â | Â | 10.158 | 0.038 |
 Heterosexual | 1438 (77.31) | 176 (80.73) | 1262 (76.86) |  |  |
 Intravenous drug use or blood exchange | 53 (2.85) | 11 (5.05) | 42 (2.56) |  |  |
 Homosexual | 308 (16.56) | 24 (11.01) | 284 (17.30) |  |  |
 Vertical | 7 (0.38) | 0 (0.00) | 7 (0.43) |  |  |
 Unknown | 54 (2.90) | 7 (3.21) | 47 (2.86) |  |  |
Mtb infection in the recent year | Â | Â | Â | 5.007 | 0.082 |
 Yes | 164 (8.82) | 28 (12.84) | 136 (8.28) |  |  |
 No | 1680 (90.32) | 188 (86.24) | 1492 (90.86) |  |  |
 Unknown | 16 (0.86) | 2 (0.92) | 14 (0.85) |  |  |
OIs in the recent 3 months |  |  |  | 15.511 | <  0.001 |
 Yes | 587 (31.56) | 94 (43.12) | 493 (30.02) |  |  |
 No | 1244 (66.88) | 122 (55.96) | 1122 (68.33) |  |  |
 Unknown | 29 (1.56) | 2 (0.92) | 27 (1.64) |  |  |
AIDS-related symptoms | Â | Â | Â | 0.532 | 0.466 |
 Yes | 252 (13.55) | 33 (15.14) | 219 (13.34) |  |  |
 No | 1608 (86.45) | 185 (84.86) | 1423 (86.66) |  |  |
WHO clinical stage | Â | Â | Â | 10.499 | 0.015 |
 I | 1068 (57.42) | 103 (47.25) | 965 (58.77) |  |  |
 II | 202 (10.86) | 29 (13.30) | 173 (10.54) |  |  |
 III | 218 (11.72) | 31 (14.22) | 187 (11.39) |  |  |
 IV | 372 (20.00) | 55 (25.23) | 317 (19.31) |  |  |
CD4+ T-cell count (cells/ml) | 211 (58, 329) | 156 (33, 294) | 220 (62.5, 333) | −3.604 | < 0.001 |
Viral Load (Log10 copies/ml) (Median, IQR) | 4.89 (4.37, 5.38) | 5.08 (4.38, 5.60) | 4.85 (4.31, 5.35) | −3.467 | 0.001 |
Cotrimoxazole use before baseline | Â | Â | Â | 1.499 | 0.221 |
 Yes | 573 (30.81) | 75 (34.40) | 498 (30.33) |  |  |
 No | 1287 (69.19) | 143 (65.60) | 1144 (69.67) |  |  |
Total | 1860 (100.00) | 218 (11.72) | 1642 (88.28) | Â | Â |